Heparin/heparan sulphate glycosaminoglycans
(GAGs) are an important subset of complex polysaccharides,
and represent an under-exploited third major class
of biological polymers, along with nucleic acids
and proteins. Recent understandings of GAG biosynthesis,
structure and function now create the opportunity
to capitalise on the large structural diversity
of GAGs in drug discovery programs. Extensive
clinical experience with various heparin products
and a good understanding of its toxicity (mainly
anticoagulant properties) suggests that GAG-based
drugs can be developed and will be well tolerated.
There are now precedents to demonstrate that compounds
of this type can be successfully synthesised economically
and in commercial quantities.
With a target of having a drug candidate ready
for Phase I clinical trials by Q4 2008, next steps
will go from completion of a proof of concept
study using human nasal polyps ex vivo and a validated
animal model, through lead optimisation, candidate
selection and a formal pre-clinical drug development
and toxicology program.
Contact Details of Program Leader
Name: A Prof Deirdre Coombe
Institution: WABRI - Curtin University
Ph: +61 8 9224 0355
Fax: +61 8 9224 0360
Email:
|
